SCHEMBL6158966

SCHEMBL6158966

CC(=O)S[C@@H]1CN(Cc2ccc(Oc3ccccc3)cc2)C(=O)[C@H]1C

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MMP2 P08253 4/20 0.40
MMP1 P03956 2/20 0.40
MMP3 P08254 2/20 0.40
MMP9 P14780 2/20 0.40
MMP13 P45452 2/20 0.40
GRM2 Q14416 1/20 0.40
EGLN1 Q9GZT9 1/20 0.40
S1PR5 Q9H228 1/20 0.39
BRD4 O60885 1/20 0.39
HRH3 Q9Y5N1 1/20 0.38
FAAH O00519 1/20 0.38
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
LTA4H P09960 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6158960 1.00 MEN1 (0.43) MEN1KMT2AMMP2MMP1MMP3
SCHEMBL6158954 1.00 MEN1 (0.43) MEN1KMT2AMMP2MMP1MMP3
SCHEMBL6160000 0.79 MEN1 (0.42) MEN1KMT2AHRH3FAAHLTA4H
SCHEMBL6157173 0.78 GRM2 (0.47) MEN1KMT2AMMP2GRM2HRH3
SCHEMBL6157168 0.78 GRM2 (0.47) MEN1KMT2AMMP2GRM2HRH3
SCHEMBL6157177 0.78 GRM2 (0.47) MEN1KMT2AMMP2GRM2HRH3
SCHEMBL6157016 0.78 HRH3 (0.44) EGLN1HRH3FAAHHCRTR1HCRTR2
SCHEMBL6158423 0.78 SMN1; SMN2 (0.45) HCRTR1HCRTR2
SCHEMBL6158416 0.78 SMN1; SMN2 (0.45) HCRTR1HCRTR2
SCHEMBL6160144 0.78 SMN1; SMN2 (0.45) HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6953789-B2 Thiol compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-10-11 US disclosed
US-20040157894-A1 Thiol compounds, their production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-08-12 US disclosed
US-6699881-B2 MATRIX METALLOPROTEASE INHIBITORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-03-02 US disclosed
US-20030078253-A1 Thiol compounds, their production and use TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) 2003-04-24 US disclosed
US-6420415-B1 Thiol compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-07-16 US disclosed
EP-1132379-A1 NOVEL THIOL DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF Takeda Chemical Industries, Ltd. (JP) 2001-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078253-A1 Thiol compounds, their production and use TST, QSOX1, SULT1E1 MEN1 3957/4885KMT2A 1898/4885MMP2 4550/4885
US-20040157894-A1 Thiol compounds, their production and use TST, SULT1E1, QSOX1 MEN1 3906/4885KMT2A 1850/4885MMP2 4468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.